我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
18
9 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
7
38.9%
已完成
2
11.1%
尚未招募
招募中
暂无批准数据
- BioNTech's BNT327, a VEGF x PD-L1 bispecific antibody, demonstrates encouraging Phase II survival data in triple-negative breast cancer (TNBC). - The bispecific antibody, combined with nab-paclitaxel, achieved a 13.5-month progression-free survival (PFS) as a first-line treatment for advanced TNBC. - These findings suggest a potential advantage over standard PD-1 blockers, positioning BNT327 as a promising therapeutic option for TNBC. - BioNTech is preparing to advance BNT327 to Phase III trials based on the positive Phase II results presented at the San Antonio Breast Cancer Symposium.
